We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current NIOX market cap is 304.4M. The company's latest EPS is GBP 0.0383 and P/E is 18.80.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 48.3M | 62.4M | 46M | 30.4M | 33.3M |
| Operating Income | -113.8M | -94.7M | -135.5M | -2.4M | 12M |
| Net Income | -117.1M | -48.3M | -33.5M | 3.6M | 16.1M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 307.4M | 246.8M | 103.1M | 86.4M | 98.5M |
| Total Liabilities | 181.5M | 162M | 37M | 19.6M | 16.6M |
| Total Equity | 125.9M | 84.8M | 66.1M | 66.8M | 81.9M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -40.6M | -25.1M | -23.9M | 1.4M | 6.7M |
| Investing | 15.6M | -9.9M | -500k | -200k | -100k |
| Financing | 20.3M | 21.9M | 4.3M | 4.1M | -500k |
| Market Cap | 304.4M |
| Price to Earnings Ratio | 18.80 |
| Price to Sales Ratio | 9.09 |
| Price to Cash Ratio | 15.62 |
| Price to Book Ratio | 3.7 |
| Dividend Yield | - |
| Shares Outstanding | 420.44M |
| Average Volume (1 week) | 376.76k |
| Average Volume (1 Month) | 1.44M |
| 52 Week Change | 21.07% |
| 52 Week High | 75.40 |
| 52 Week Low | 54.00 |
| Spread (Intraday) | 0.2 (0.28%) |
| Company Name | Niox Group Plc |
| Address |
hayakawa building oxfordshire OX4 4GB |
| Website | https://www.niox.com/en-gb/legal-notice |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
